Metastatic Breast Cancer
Adding experimental tucatinib to the standard of care of Herceptin and Xeloda improved both progression-free survival and overall survival in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.
The combination of Perjeta, Herceptin, and an aromatase inhibitor led to longer progression-free survival than only Herceptin and an aromatase inhibitor in women diagnosed with advanced-stage HER2-positive, hormone-receptor-positive disease.
A preliminary study suggests that a targeted therapy may be able to make hormone-receptor-positive breast cancers that have stopped responding to hormonal therapy start responding again.
Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is somewhat better than Zometa at lowering the risk of bone complications in women diagnosed with breast cancer that has spread to the bones.
A small, early study found that treating women diagnosed with metastatic, HER2-positive breast cancer that has spread to the brain with a combination of Tykerb and Xeloda can shrink the cancer in some women.
Research suggests that people diagnosed with advanced-stage breast or prostate cancer who get Xgeva are about twice as likely to develop osteonecrosis of the jaw compared to people with other advanced-stage cancers treated with Xgeva.
Experimental abemaciclib in combination with Faslodex offered better progression-free survival than Faslodex alone in women diagnosed with metastatic, hormone-receptor-positive, HER2-negative breast cancer.
Adding Faslodex to Arimidex as the first treatment for metastatic hormone-receptor-positive breast cancer improved overall survival by nearly 8 months compared to Arimidex alone, according to a study.
Adding Ibrance to Faslodex as a first treatment for advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that either came back (recurred) more than 1 year after completing 5 or more years of hormonal therapy or was metastatic at first diagnosis improved progression-free survival compared to Faslodex alone.
For people with HER2-positive breast cancer that has spread to the brain, adding Tukysa to standard treatment improved survival and reduced the risk that the brain lesions would grow.
The combination of Tykerb, Herceptin, and an aromatase inhibitor seems better than just Herceptin and an aromatase inhibitor or just Tykerb and an aromatase inhibitor for treating metastatic HER2-positive, hormone-receptor-positive breast cancer in postmenopausal women.
The American Society of Clinical Oncology has issued new recommendations on using biomarkers to make metastatic breast cancer treatment decisions.
People diagnosed with metastatic cancer that has spread to the bones can safely participate in supervised exercise programs, according to a review of 17 studies.
Research suggests that Xgeva is better than Zometa at reducing the risk of bone complication and improves quality of life more in women diagnosed with metastatic breast cancer that has spread to the bones.
The characteristics of a breast cancer -- including hormone receptor status and HER2 status -- can change over time. These changes may happen because the cancer cells change themselves or because treat...
A study has found that women diagnosed with recurrent or metastatic, hormone-receptor-positive breast cancer lived longer when they got 500 mg of Faslodex compared to women who got 250 mg of Faslodex.
A study has found that using Faslodex as the first treatment for hormone-receptor-positive, advanced-stage breast cancer offers better survival than using Arimidex as the first treatment.
A study by researchers at the Mayo Clinic suggests that the large studies on the link between CYP2D6 and tamoxifen's effectiveness may be flawed because the studies did the genetic testing on samples of tissue from the breast cancer rather than on healthy tissue.
The FDA has granted accelerated approval for using the targeted therapy Ibrance in combination with Femara to treat advanced-stage, estrogen-receptor-positive, HER2-negative breast cancer that hadn't been treated with hormonal therapy before in postmenopausal women.
A study has found that Ibrance combined with Faslodex more than doubled progression-free survival compared to Faslodex alone in postmenopausal women diagnosed with hormone-receptor-positive, HER2-negative advanced-stage breast cancer that had grown while being treated with hormonal therapy.
On Nov. 13, 2020, the FDA approved the immunotherapy Keytruda in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.
Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.
On April 17, 2020, the FDA approved Tukysa in combination with Herceptin and Xeloda to treat metastatic HER2-positive breast cancer, or locally advanced HER2-positive disease that can't be completely removed with surgery, after the cancer had been treated with at least one anti-HER2 medicine.
Adding Tukysa to the standard of care of Herceptin and Xeloda continued to improve both progression-free and overall survival in people diagnosed with either metastatic or unresectable locally advanced HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.